Efficacy of bortezomib as first-line treatment for patients with multiple myeloma

Utkarsh Painuly, Shaji K Kumar

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)53-73
Number of pages21
JournalClinical Medicine Insights: Oncology
Volume7
DOIs
StatePublished - 2012

Fingerprint

Multiple Myeloma
Proteasome Inhibitors
Therapeutics
Survival
Patient Compliance
Cyclophosphamide
Dexamethasone
Bortezomib
Guidelines
Apoptosis
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms

Keywords

  • Bortezomib
  • Clinical outcomes
  • Efficacy
  • First-line
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology

Cite this

Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. / Painuly, Utkarsh; Kumar, Shaji K.

In: Clinical Medicine Insights: Oncology, Vol. 7, 2012, p. 53-73.

Research output: Contribution to journalArticle

@article{5c0d89b325ec441490abfec7ed09a284,
title = "Efficacy of bortezomib as first-line treatment for patients with multiple myeloma",
abstract = "Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma.",
keywords = "Bortezomib, Clinical outcomes, Efficacy, First-line, Multiple myeloma",
author = "Utkarsh Painuly and Kumar, {Shaji K}",
year = "2012",
doi = "10.4137/CMO.S7764",
language = "English (US)",
volume = "7",
pages = "53--73",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Efficacy of bortezomib as first-line treatment for patients with multiple myeloma

AU - Painuly, Utkarsh

AU - Kumar, Shaji K

PY - 2012

Y1 - 2012

N2 - Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma.

AB - Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single/combination agent for front-line treatment of multiple myeloma.

KW - Bortezomib

KW - Clinical outcomes

KW - Efficacy

KW - First-line

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84874734388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874734388&partnerID=8YFLogxK

U2 - 10.4137/CMO.S7764

DO - 10.4137/CMO.S7764

M3 - Article

VL - 7

SP - 53

EP - 73

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -